AB308 is an anti-TIGIT antibody that is FcR-enabled.
|Developed By||Arcus Biosciences, Inc.|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.